Profound Medical Corp.

PRN

CA74319B5027

Advanced Medical Equipment & Technology

Delayed Toronto S.E. Other stock markets 07:00:00 04/06/2024 pm IST			5-day change	1st Jan Change
10.35 ^CAD	+0.49%		+3.50%	-6.76%

15/05	Transcript : Profound Medical Corp. - Shareholder/Analyst Call
14/05	Sector Update: Health Care Stocks Steady Premarket Tuesday	MT

Profound Medical Corp. Elects Kris Shah to Board of Director

May 19, 2022 at 03:13 am IST

Profound Medical Corp. at the annual and special meeting of shareholders held on May 18, 2022 elected Kris Shah to board of director.

Latest news about Profound Medical Corp.

Transcript : Profound Medical Corp. - Shareholder/Analyst Call	15/05
Sector Update: Health Care Stocks Steady Premarket Tuesday	14/05	MT
Profound Medical Receives FDA Approval for AI-Powered Prostate Disease Device --Shares Advance Pre-Bell	14/05	MT
Profound Medical Receives U.S. FDA Clearance for "Contouring Assistant" AI Module	14/05	MT
Profound Medical Brief: Says Received U.S. FDA 510(k) Clearance for 'Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan	14/05	MT
Profound Medical Receives U.S. FDA 510(K) Clearance for Contour Assistant AI Module That Enables Creation of an Automated Tulsa Treatment Plan	14/05	CI
Profound Reports a Narrower First-Quarter Loss; Provides 2024 Revenue Guidance	10/05	MT
Transcript : Profound Medical Corp., Q1 2024 Earnings Call, May 09, 2024	10/05
Profound Medical Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Profound Medical Brief: Expects total revenue for FY24 to be in the range of US$11.0-$12.0 million, which represents 53% to 67% growth compared to its prior year revenue	10/05	MT
Profound Medical Brief: Recorded Q1 revenue of approximately $1.91 million, with $1.48 million from recurring revenue; Issues Full-Year 2024 Revenue Guidance	10/05	MT
Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024	10/05	CI
Profound Medical Says Clinical Evidence Points to Potential of Its TULSA Procedure as a Treatment for Prostate Cancer	07/05	MT
Profound Medical Brief: Adds Clinical evidence Continues to highlight TULSA's "Ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH"	07/05	MT
Profound Medical Brief: Says "Growing Body of Clinical Evidence" Points to Potential of Its TULSA Procedure "Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum"	07/05	MT
Transcript : Profound Medical Corp. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM	13/03
Alliance Global Partners Trims Price Target on Profound Medical to $10.80 From $12.75, Maintains Buy Rating	11/03	MT
Stifel Adjusts Price Target on Profound Medical to $9 From $11, Keeps Hold Rating	08/03	MT
Profound Medical Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03	CI
Transcript : Profound Medical Corp., Q4 2023 Earnings Call, Mar 07, 2024	08/03
Profound Medical Reports Q4 Net Loss of US$0.42 Per Share, Announces COO Appointment	08/03	MT
Profound Medical Brief: Announcing promotion of Mathieu Burtnyk, from SVP Product Leader to Chief Operating Officer	08/03	MT
Profound Medical Brief: Q4 2023 net loss was approximately US$8.9 million, or $0.42 per common share	08/03	MT
North American Morning Briefing : Powell Still in the Spotlight; ECB Rate Decision Looms	07/03	DJ
Profound Medical Collaborates With Siemens Healthineers to Expand Physician and Patient Access to the TULSA Procedure	27/02	MT

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer and the transition zone in large volume benign prostatic hyperplasia. It is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Sector

Advanced Medical Equipment & Technology

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Profound Medical Corp.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

10.3 CAD

Average target price

12.5 CAD

Spread / Average Target

+21.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
PROFOUND MEDICAL CORP.	-6.76%	18Cr
THERMO FISHER SCIENTIFIC	+7.88%	22TCr
DANAHER CORPORATION	+13.88%	19TCr
INTUITIVE SURGICAL, INC.	+19.93%	14TCr
BOSTON SCIENTIFIC CORPORATION	+30.79%	11TCr
SIEMENS HEALTHINEERS AG	+3.04%	6.43TCr
EDWARDS LIFESCIENCES CORPORATION	+14.66%	5.29TCr
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+2.06%	4.95TCr
AGILENT TECHNOLOGIES, INC.	-5.16%	3.83TCr
GE HEALTHCARE TECHNOLOGIES INC.	+0.26%	3.52TCr

Other Advanced Medical Equipment & Technology